SCHEMBL1745124

SCHEMBL1745124

O=C(O)CCCc1cccc(OC2CCc3ccccc32)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFRA3 O60609 2/20 0.52
GFRA2 O00451 1/20 0.52
RET P07949 1/20 0.49
FFAR1 O14842 5/20 0.47
SLC6A3 Q01959 2/20 0.44
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746725 0.86 GFRA3 (0.50) GFRA3GFRA2RETFFAR1SMN1; SMN2
SCHEMBL1746652 0.86 GFRA3 (0.63) GFRA3GFRA2RETFFAR1
SCHEMBL1632826 0.83 FFAR1 (0.64) FFAR1FFAR4
SCHEMBL27641091 0.82 PPARD (0.51) FFAR1SLC6A3HDAC3MAPK1ADRA1A
SCHEMBL16844693 0.81 GFRA3 (0.52) GFRA3GFRA2RETFFAR1FFAR4
SCHEMBL1744666 0.80 GFRA3 (0.53) GFRA3GFRA2RETFFAR1
SCHEMBL21810402 0.80 SUCNR1 (0.54) GFRA3GFRA2RETFFAR1FFAR4
SCHEMBL1633343 0.80 FFAR1 (0.57) FFAR1FFAR4EPHX2
SCHEMBL1745432 0.80 FFAR1 (0.57) FFAR1FFAR4EPHX2
SCHEMBL1633344 0.80 FFAR1 (0.57) FFAR1FFAR4EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR GFRA3 412/4885GFRA2 338/4885RET 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.